https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54994 Wed 27 Mar 2024 16:38:54 AEDT ]]> The impact of a regionally based translational cancer research collaborative in Australia using the FAIT methodology https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54997 Wed 27 Mar 2024 16:38:22 AEDT ]]> FDG-PET parameters predict for recurrence in anal cancer - results from a prospective, multicentre clinical trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45220 Wed 26 Oct 2022 19:56:49 AEDT ]]> Optimisation and validation of an integrated magnetic resonance imaging-only radiotherapy planning solution https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45142 Wed 26 Oct 2022 15:43:14 AEDT ]]> Automatic radiotherapy delineation quality assurance on prostate MRI with deep learning in a multicentre clinical trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43531 Wed 21 Sep 2022 11:32:29 AEST ]]> Real-Time Image Guided Ablative Prostate Cancer Radiation Therapy: Results From the TROG 15.01 SPARK Trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42282 Wed 16 Aug 2023 14:37:30 AEST ]]> A prospective study of nomogram-based adaptation of prostate radiotherapy target volumes https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24716 Wed 11 Apr 2018 14:27:57 AEST ]]> Infections after fiducial marker implantation for prostate radiotherapy: are we underestimating the risks? https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27681 Wed 11 Apr 2018 13:22:02 AEST ]]> Coeliac patients are undiagnosed at routine upper endoscopy https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20670 60: 100%, 81% and 50% respectively, p = 0.03); 28% of newly diagnosed CD patients were aged over 60 years. Endoscopic appearance was a useful diagnostic tool in only 51% (18/35) of CD patients. Coeliac antibodies were positive in 34/35 CD patients (sensitivity 97%). Conclusions: Almost one quarter of new cases of CD presented with atypical symptoms and half of the new cases had unremarkable duodenal mucosa. At least 10% of new cases of celiac disease are likely to be undiagnosed at routine upper endoscopy, particularly patients over 60 years who more commonly present atypically. All new CD patients could be identified in this study by performing pre-operative celiac antibody testing on all patients presenting for OGD and proceeding to biopsy only positive antibody patients and those presenting with either Major CI or abnormal duodenal mucosa for an estimated cost of AUS$4,629 and AUS$3,710 respectively.]]> Wed 11 Apr 2018 10:15:34 AEST ]]> Investigation on the performance of dedicated radiotherapy positioning devices for MR scanning for prostate planning https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28129 3. The external body deformation caused a mean dose reduction of 0.6 ± 0.3 Gy, while the coverage reduced by 22% ± 13% and 27% ± 6% in V₉₈ and V₁₀₀, respectively. A dedicated MR simulation setup for prostate radiotherapy is essential to ensure the agreement between planning anatomy and treatment anatomy. The image signal was reduced after applying the coil mount, but no significant effect was found on prostate contouring.]]> Wed 11 Apr 2018 09:52:08 AEST ]]> Spinal multiparametric MRI and DEXA changes over time in men with prostate cancer treated with androgen deprivation therapy: a potential imaging biomarker of treatment toxicity https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33054 5 % BMD loss after 1 year had triple the percentage increase in MRS FF at 6 months (61.1 % vs. 20.9 %, p = 0.19). Conclusions: Changes are observed on L-spine MRI after 6 months of ADT. Further investigation is warranted of MRS change as a potential predictive biomarker for later BMD loss.]]> Wed 09 Mar 2022 16:02:16 AEDT ]]> Technical note: TROG 15.01 SPARK trial multi-institutional imaging dose measurement https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33853 Wed 04 Sep 2019 10:04:12 AEST ]]> Visualising the urethra for prostate radiotherapy planning https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49004 Wed 03 May 2023 12:17:09 AEST ]]> Real-time intrafraction prostate motion during linac based stereotactic radiotherapy with rectal displacement https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33946 Wed 02 Mar 2022 14:29:12 AEDT ]]> Reduced motion and improved rectal dosimetry through endorectal immobilization for prostate stereotactic body radiotherapy https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37462 Wed 02 Mar 2022 14:28:00 AEDT ]]> Regression and statistical shape model based substitute CT generation for MRI alone external beam radiation therapy from standard clinical MRI sequences https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33939 Wed 02 Mar 2022 14:26:19 AEDT ]]> Rectal protection in prostate stereotactic radiotherapy: a retrospective exploratory analysis of two rectal displacement devices https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:31943 P = 0.0012). Comparison (2) demonstrated a moderate difference with centre 2 plans producing slightly lower rectal doses (P = 0.013). Comparison (3) further demonstrated that Rectafix returned lower mean doses than SpaceOAR (P < 0.001). Although all dose levels were in favour of Rectafix, in absolute terms differences were small (2.6-9.0%). Conclusions: In well-selected prostate SBRT patients, Rectafix and SpaceOAR RDD's provide approximately equivalent rectal sparing.]]> Wed 02 Mar 2022 14:25:36 AEDT ]]> Non-contrast based approach for liver function quantification using Bayesian-based intravoxel incoherent motion diffusion weighted imaging: A pilot study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53472 Tue 28 Nov 2023 15:54:21 AEDT ]]> Phase I trial of hypofractionated chemoradiotherapy in the palliative management of esophageal and gastro-esophageal cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51990 Tue 26 Sep 2023 10:53:57 AEST ]]> Comparison of synthetic computed tomography generation methods, incorporating male and female anatomical differences, for magnetic resonance imaging-only definitive pelvic radiotherapy https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48543 Tue 21 Mar 2023 15:42:15 AEDT ]]> Validation of an MRI-only planning workflow for definitive pelvic radiotherapy https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48126 99% for criteria of 3%/2 mm and 2%/2 mm. With dose criteria of 1%/1 mm, the pass rate was higher for the male cohort at 96.3% than the female cohort at 93.4%. MRI to sCT anatomical agreement for bone and body delineated contours was assessed, with a resulting Dice score of 0.91 ± 0.2 (mean ± 1 SD) and 0.97 ± 0.0 for the male cohort respectively; and 0.96 ± 0.0 and 0.98 ± 0.0 for the female cohort respectively. The mean absolute error in Hounsfield units (HUs) within the entire body for the male and female cohorts was 59.1 HU ± 7.2 HU and 53.3 HU ± 8.9 HU respectively. Conclusions: A multi-atlas based method for sCT generation can be applied to a standard T1-weighted MRI sequence for male and female pelvic patients. The implications of this study support MRI only planning being applied more broadly for both male and female pelvic sites.]]> Tue 21 Mar 2023 15:07:30 AEDT ]]> Clinical target volume delineation quality assurance for MRI-guided prostate radiotherapy using deep learning with uncertainty estimation https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51626 Tue 12 Sep 2023 15:40:55 AEST ]]> Clinical validation of the Varian Truebeam intra-fraction motion review (IMR) system for prostate treatment guidance https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51605 20% compared to treatment without IMR. Calculated D98% of IMR monitored treatments with motion was within 1.5% of plans without motion.]]> Tue 12 Sep 2023 13:35:22 AEST ]]> A multi-center prospective study for implementation of an MRI-only prostate treatment planning workflow https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39881 Tue 04 Oct 2022 15:37:28 AEDT ]]> Management of early anal cancer: need for guidelines and standardisation https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33908 Thu 27 Jan 2022 15:58:48 AEDT ]]> The first clinical implementation of a real-time six degree of freedom target tracking system during radiation therapy based on Kilovoltage Intrafraction Monitoring (KIM) https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34638 Patient: A patient with prostate adenocarcinoma undergoing SBRT with 36.25 Gy, delivered in 5 fractions was enrolled in the study. 6DoF KIM technology: 2D positions of three implanted gold markers in each of the kV images (125 kV, 10 mA at 11 Hz) were acquired continuously during treatment. The 2D → 3D target position estimation was based on a probability distribution function. The 3D → 6DoF target rotation was calculated using an iterative closest point algorithm. The accuracy and precision of the KIM method was measured by comparing the real-time results with kV-MV triangulation. Results: Of the five treatment fractions, KIM was utilised successfully in four fractions. The intrafraction prostate motion resulted in three couch shifts in two fractions when the prostate motion exceeded the pre-set action threshold of 2 mm for more than 5 s. KIM translational accuracy and precision were 0.3 ± 0.6 mm, −0.2 ± 0.3 mm and 0.2 ± 0.7 mm in the Left-Right (LR), Superior-Inferior (SI) and Anterior-Posterior (AP) directions, respectively. The KIM rotational accuracy and precision were 0.8° ± 2.0°, −0.5° ± 3.3° and 0.3° ± 1.6° in the roll, pitch and yaw directions, respectively. Conclusion: This treatment represents, to the best of our knowledge, the first time a cancer patient’s tumour position and rotation have been monitored in real-time during treatment. The 6 DoF KIM system has sub-millimetre accuracy and precision in all three translational axes, and less than 1° accuracy and 4° precision in all three rotational axes.]]> Thu 24 Mar 2022 11:35:51 AEDT ]]> The impact of contour variation on tumour control probability in anal cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32548 Thu 24 Mar 2022 11:30:42 AEDT ]]> Phase 2 multicenter study of gantry-based stereotactic radiotherapy boost for intermediate and high risk prostate cancer (PROMETHEUS) https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34741 Thu 17 Feb 2022 09:29:26 AEDT ]]> Patients' experiences of preparation for radiation therapy: a qualitative study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:31394 Thu 17 Feb 2022 09:28:54 AEDT ]]> Oncologist provision of smoking cessation support: A national survey of Australian medical and radiation oncologists https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43332 Thu 15 Sep 2022 14:57:43 AEST ]]> Fast automated segmentation of multiple objects via spatially weighted shape learning https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29622 Thu 09 Dec 2021 11:02:48 AEDT ]]> Should brachytherapy be added to external beam radiotherapy for prostate cancer? https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47327 Thu 02 May 2024 15:29:57 AEST ]]> Prostate Cancer Radiotherapy: An Evolving Paradigm https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41252 Sat 30 Jul 2022 12:54:21 AEST ]]> Incremental changes verses a technological quantum leap: the additional value of intensity-modulated radiotherapy beyond image-guided radiotherapy for prostate irradiation https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20392 Sat 24 Mar 2018 07:58:08 AEDT ]]> Circulating tumor cell detection in high-risk non-metastatic prostate cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21027 Sat 24 Mar 2018 07:50:34 AEDT ]]> Optimizing radiation therapy quality assurance in clinical trials: a TROG 08.03 RAVES substudy https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26274 Sat 24 Mar 2018 07:40:16 AEDT ]]> Patterns of management and surveillance imaging amongst medical oncologists in Australia for stage i testicular cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28610 Sat 24 Mar 2018 07:38:55 AEDT ]]> MRI simulation: end-to-end testing for prostate radiation therapy using geometric pelvic MRI phantoms https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27970 Sat 24 Mar 2018 07:38:43 AEDT ]]> The role of FDG-PET in the initial staging and response assessment of anal cancer: a systematic review and meta-analysis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26357 Sat 24 Mar 2018 07:35:51 AEDT ]]> Automatic substitute computed tomography generation and contouring for magnetic resonance imaging (MRI)-alone external beam radiation therapy from standard MRI sequences https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22668 Sat 24 Mar 2018 07:12:10 AEDT ]]> Real-time in vivo rectal wall dosimetry using MOSkin detectors during linac based stereotactic radiotherapy with rectal displacement https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43577 Skin detectors were an effective tool for measuring dose delivered to the anterior rectal wall in real time during prostate SBRT boost treatments for the purpose of both ensuring the rectal doses remain within acceptable limits during the treatment and for the verification of final rectal doses.]]> Mon 26 Sep 2022 10:27:37 AEST ]]> Cone beam computed tomography image guidance within a magnetic resonance imaging-only planning workflow https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55077 Mon 08 Apr 2024 14:16:50 AEST ]]> Determination of hepatic extraction fraction with gadoxetate low-temporal resolution DCE-MRI-based deconvolution analysis: validation with ALBI score and Child-Pugh class https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51930 Fri 22 Sep 2023 11:07:30 AEST ]]> Genitourinary Quality-of-Life Comparison Between Urethral Sparing Prostate Stereotactic Body Radiation Therapy Monotherapy and Virtual High-Dose-Rate Brachytherapy Boost https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52691 Fri 20 Oct 2023 15:54:55 AEDT ]]> A prospective, multi-centre trial of multi-parametric MRI as a biomarker in anal carcinoma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38429 p = 0.04, ROC AUC 0.90) and standard deviation (SD) (p = 0.02, ROC AUC 0.90), week 2 skewness (p = 0.02, ROC AUC 0.91) and SD (p = 0.01, ROC AUC 0.94), week 4 kurtosis (p = 0.01, AUC 0.92) and SD (p = 0.01, ROC AUC 0.96). Changes in minimum ADC between baseline and week 2 (p = 0.02, ROC AUC 0.94) and baseline and week 4 (p = 0.02, ROC AUC 0.94) were prognostic for local recurrence. For prediction of any recurrence, ADC minimum (p = 0.02, ROC AUC 0.87) and SD (p = 0.01, ROC AUC 0.85) at baseline, and ADC maximum (p = 0.03, ROC AUC 0.77) and SD (p = 0.02, ROC AUC 0.81) at week 4 were significant. On LASSO logistic regression, ADC minimum and SD at baseline were retained for any recurrence. The only significant finding for DCE-MRI was a correlation of k-trans min at the second follow-up with local recurrence (p = 0.05, AUC 0.84). Conclusion: Several ADC parameters at various time points correlate with recurrence suggesting DW-MRI is a potential biomarker for SCCAC.]]> Fri 10 Sep 2021 12:16:47 AEST ]]>